Evidence map›Paper›PMID 41705755›Full record

ArticleJACC. CardioOncology2026

Polygenic Risk for Cardiometabolic and Cardiovascular Disease in a Multiethnic Cohort of Breast Cancer Survivors.

Peter N Fiorica, Alexa Zimbalist, Haiyang Sheng, Cecile A Laurent, Janise M Roh, Valerie S Lee, Isaac J Ergas, Jennifer Delmerico, Qianqian Zhu, Richard K Cheng and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. CardioOncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Risk-guided cardioprotection in cardio-oncology.Nature cardiovascular research · 2026
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Peter N FioricaDepartment of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Alexa ZimbalistDivision of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.
Haiyang ShengDepartment of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Cecile A LaurentDivision of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.
Janise M RohDivision of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.
Valerie S LeeDivision of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.
Isaac J ErgasDivision of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.
Jennifer DelmericoDepartment of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Qianqian ZhuDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Richard K ChengUniversity of Washington School of Medicine, Seattle, Washington, USA; Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Eileen Rillamas-SunFred Hutchinson Cancer Center, Seattle, Washington, USA.
Carlos IribarrenDivision of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.
Jamal S RanaDivision of Research, Kaiser Permanente Northern California, Pleasanton, California, USA; Oakland Medical Center, Kaiser Permanente Northern California, Oakland, California, USA.
Mai Nguyen-HuynhDivision of Research, Kaiser Permanente Northern California, Pleasanton, California, USA; Walnut Creek Medical Center, Kaiser Permanente Northern California, Walnut Creek, California, USA.
Dawn L HershmanHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, USA.
Christine B AmbrosoneDepartment of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Lawrence H KushiDivision of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.
Heather GreenleeUniversity of Washington School of Medicine, Seattle, Washington, USA; Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Marilyn L KwanDivision of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.
Song YaoDepartment of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA. Electronic address: song.yao@roswellpark.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBecause of cancer treatment-related cardiotoxicities, women with histories of breast cancer are at increased risk for cardiovascular disease (CVD). Many polygenic scores (PGS) have been developed for predicting risk for CVD-related conditions in the general population, but their performance in breast cancer patients remains largely unexplored.

objectivesThe aim of this study was to examine the performance of PGS for CVD-related traits to predict incident cardiometabolic disorder (CMD) and CVD in women with histories of breast cancer.

methodsIn a prospective multiethnic cohort of 3,620 breast cancer survivors, 27 PGS for CVD-related traits were we computed, and their associations with 12 incident CMD and CVD events were examined. The performance of these PGS was compared relative to clinical covariates-only models and by cardiotoxic cancer treatment.

resultsTwenty-three significant associations were identified after Bonferroni correction between PGS and CMD or CVD events in breast cancer patients. Although the model performance of PGS and multi-PGS added to or combined with clinical models for CMD and CVD risk prediction was numerically greater, these were not statistically significant. For some outcomes, PGS performed worse among patients who received cardiotoxic cancer treatments.

conclusionsAlthough there may be potential value of PGS in predicting the risk for CMD and CVD events in women with histories of breast cancer, current PGS performance is limited. This work highlights the need to develop de novo PGS in breast cancer patients and to include ancestrally diverse patient populations.

Indexed as

biomarkersbreast cancercancer survivorshipcoronary artery diseasediabetesepidemiologygeneticsGWASrisk predictionwomen’s oncology

Identifiers

PMID41705755
PMCPMC12922620

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.